This page contains a Flash digital edition of a book.
Evidence for Anti-vascular Endothelial Growth Factor Treatment of Diabetic Macular Oedema


from this trial suggest that subconjunctival rapamycin is safe in the treatment of patients with DME; however, conclusions cannot be drawn regarding its therapeutic efficacy in DME, since the findings could also be attributed to the natural history of DME or laser treatment. In order to demonstrate the possible therapeutic effect of rapamycin a large randomised clinical trial must be designed.


Conclusions


VEGF plays a key role in promoting angiogenesis and vascular leakage and today represents an attractive candidate as a therapeutic target in the treatment and management of diabetic retinopathy. The advent of intravitreal anti-VEGF drugs has opened a new era for the management of DME. While focal/grid laser remains a standard treatment for DME and is supported by evidence provided by large-scale studies,51


the use of anti-VEGF substances in clinical


practice has showed encouraging results. Most of the studies reported in this article were well-designed clinical trials with the objective of demonstrating both the therapeutic effect of anti-VEGF drugs and data regarding their safety. However, only larger trials can consolidate the use of anti-VEGF drugs in the clinical routine with the objective of creating guidelines for the management of DME. Another


1. Kempen JH, O’Colmain BJ, Leske MC, et al., Eye Diseases Prevalence Research Group, The prevalence of diabetic retinopathy among adults in the United States, Arch Ophthalmol, 2004;122:552–63.


2. Klein R, Retinopathy in a population-based study, Trans Am Ophthalmol Soc, 1992;90:561–94.


3. Orchard TJ, Dorman JS, Maser RE, et al., Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II, Diabetes, 1990;39:1116–24.


4. Wild S, Roglic G, Green A, et al., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030, Diabetes Care, 2004;27:1047–53.


5. Bandello F, Parodi MB, Lanzetta P, et al., Diabetic macular edema, Dev Ophthalmol, 2010;47:73–110.


6. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z, Vascular endothelial growth factor (VEGF) and its receptors, FASEB J, 1999;13:9–22.


7. Grant MB, Afzal A, Spoerri P, et al., The role of growth factors in the pathogenesis of diabetic retinopathy, Expert Opin Investig Drugs, 2004;13:1275–93.


8. Plate KH, Breier G, Weich HA, Risau W, Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo, Nature, 1992;359:845–8.


9. Shweiki D, Itin A, Soffer D, Keshet E, Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis, Nature, 1992;359:843–5.


10. Aiello LP, Avery RL, Arrigg PG, et al., Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders, N Engl J Med, 1994;331:1480–7.


11. Gardner TW, Antonetti DA, Barber AJ, et al., Diabetic retinopathy: more than meets the eye, Surv Ophthalmol, 2002;47(Suppl. 2):S253–62.


12. Chun DW, Heier JS, Topping TM, et al., A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema, Ophthalmology, 2006;113:1706–12.


13. Nguyen QD, Tatlipinar S, Shah SM, et al., Vascular endothelial growth factor is a critical stimulus for diabetic macular edema, Am J Ophthalmol, 2006;142:961–9.


14. Nguyen QD, Shah SM, Heier JS, et al., Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study, Ophthalmology, 2009;116:2175–81.e1


15. Nguyen QD, Shah SM, Khwaja AA, et al., READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study, Ophthalmology, 2010;117:2146–51.


16. Wolf S, Massin P, Bandello F, et al., RESOLVE Study Group. Safety and Efficacy of Ranibizumab Treatment in Patients With Diabetic Macular Edema: 12-Months Results of the Resolve Study, Presented at: Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, FL, May 2–7, 2009.


17. Massin P, Bandello F, Garweg JG, et al., Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study, Diabetes Care, 2010;33:2399–405.


18. Mitchell P, Bandello F, Schmidt-Erfurth U, et al., The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema, Ophthalmology, 2011;118:615–25.


19. Massin P, Audren F, Haouchine B, et al., Intravitreal


Different clinical trials have demonstrated an adequate safety profile for anti-VEGF substances, even though a long-term analysis of systemic and ocular side effects is needed. In essence, anti-VEGF drugs have revolutionised the treatment of DME. It is likely that combination treatment with laser photocoagulation can be practical and effective in the management of DME. n


triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial, Ophthalmology, 2004;111:218–24.


20. Gillies MC, Sutter FK, Simpson JM, et al., Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial, Ophthalmology, 2006;113:1533–8.


21. Elman MJ, Bressler NM, Qin H, et al., Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Diabetic Retinopathy Clinical Research Network, Ophthalmology, 2011;118:609–14.


22. Googe J, Brucker AJ, Bressler NM, et al., Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation, Retina, 2011;31:1009–27.


23. Two Pivotal Phase III Lucentis Studies Showed Patients With Diabetic Macular Edema Experienced Significant Improvements in Vision and Fewer Developed More Advanced Retinopathy, 2011. Available at: www.gene.com (accessed 28 June 2011).


24. Cunningham ET Jr, Adamis AP, Altaweel M, et al., Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema, Ophthalmology, 2005;112:1747–57.


25. Sultan MB, Zhou D, Loftus J, et al., A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema, Ophthalmology, 2011;118:1107–18.


26. Scott IU, Edwards AR, Beck RW, et al., for the Diabetic Retinopathy Clinical Research Network, A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema, Ophthalmology, 2007;114:1860–7.


27. Lam DS, Lai TY, Lee VY, et al., Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial, Retina, 2009;29:292–9.


28. Arevalo JF, Sanchez JG, Wu L, et al., Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan- American Collaborative Retina Study Group at 24 months, Ophthalmology, 2009;116:1488–97, 1497.e1.


29. Kook D, Wolf A, Kreutzer T, et al., Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema, Retina, 2008;28:1053–60.


30. Paccola L, Costa RA, Folgosa MS, et al., Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study), Br J Ophthalmol, 2008;92:76–80.


31. Shimura M, Nakazawa T, Yasuda K, et al., Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema, Am J Ophthalmol, 2008;145:854–61.


32. Soheilian M, Ramezani A, Obudi A, et al., Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema, Ophthalmology, 2009;116:1142–50.


33. Soheilian M, Ramezani A, Yaseri M, et al., Initial macular thickness and response to treatment in diabetic macular edema, Retina, 2011;31:1564–73.


34. Arevalo JF, Sanchez JG, Lasave AF, et al., Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010


GLADAOF Lecture, J Ophthalmol, 2011;2011:584238.


35. Michaelides M, Kaines A, Hamilton RD, et al., A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of Diabetic Macular Edema (BOLT Study). 12 Month data: Report 2, Ophthalmology, 2010;117:1078–86.


36. Economides AN, Carpenter LR, Rudge JS, et al., Cytokine traps: multi-component, high-affinity blockers of cytokine action, Nat Med, 2003;9:47–52.


37. Holash J, Davis S, Papadopoulos N, et al., VEGF-Trap: a VEGF blocker with potent antitumor effects, Proc Natl Acad Sci USA, 2002;99:11393–8.


38. Stewart MW, Rosenfeld PJ, Predicted biological activity of intravitreal VEGF Trap, Br J Ophthalmol, 2008;92:667–8.


39. Do DV, Nguyen QD, Shah SM, et al., An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor trap-eye in patients with diabetic macular oedema, Br J Ophthalmol, 2009;93:144–9.


40. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al., The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema, Ophthalmology, 2011;118(9):1819–26.


41. Reich SJ, Fosnot J, Kuroki A, et al., Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model, Mol Vis, 2003;9:210–6.


42. Shen J, Samul R, Silva RL, et al., Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1, Gene Ther, 2006;13:225–34.


43. Singerman LJ, Combination therapy using the small interfering RNA bevasiranib, Retina, 2009;29(6 Suppl.):S49–50.


44. Singerman LJ, Intravitreal bevasiranib in exudative age-related macular degeneration or diabetic macular edema, Presented at: 25th Annual Meeting of the American Society of Retina Specialists, Indian Wells, CA, 1–5 December 2007.


45. A Phase 3, Randomized, Double-masked, Parallel-assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis Compared With Lucentis Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD). ClinicalTrials.gov identifier NCT00499590.


46. Sausville EA, Elsayed Y, Monga M, Kim G, Signal transduction- directed cancer treatments, Annu Rev Pharmacol Toxicol, 2003;43:199–231.


47. Guba M, von Breitenbuch P, Steinbauer M, et al., Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, Nat Med, 2002;8:128–35.


48. Sehgal SN, Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression, Clin Biochem, 1998;31:335–40.


49. Blumenkranz MS, Dugel PU, Solley WA, et al., A Randomized Dose-Escalation Trial of Locally-Administered Sirolimus to Treat Diabetic Macular Edema, Presented at: Association of Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, Florida, US, 27 April–1 May 2008.


50. Krishnadev N, Forooghian F, Cukras C, et al., Subconjunctival sirolimus in the treatment of diabetic macular edema, Graefes Arch Clin Exp Ophthalmol, 2011;249:1627–33.


51. ETDRS Research Group, Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group, Ophthalmology, 1987;94:761–74.


aspect that must be highlighted is the efficacy of anti-VEGF drugs over longer follow-up periods. Most controlled studies focus on one- or two-year results, but long-term results are unavailable. It would be of the utmost importance to demonstrate that anti-VEGF drugs are able to provide therapeutic effects over a long period of time, and to compare these effects with those of laser treatment, which is characterised by a slow, but sustained therapeutic effect that most likely is more efficient many years after its employment. The use of combination therapy including anti-VEGF and focal/grid laser treatment has provided encouraging results and must also be evaluated over a long timespan. In particular, the combination of laser application and intravitreal anti-VEGF can reduce the number of injections without a negative effect on visual function, in an attempt to lessen the burden of the therapy for both patients and doctors.


EUROPEAN ENDOCRINOLOGY


41


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68